Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saracatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 18/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | CSK | P41240 | 2/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saracatinib SCHEMBL29380648 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL29357263 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL29487213 | 1.00 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4255230 | 0.99 | SRC (0.99) | SRCKDREGFRLCKYES1 | |
| SCHEMBL3203253 | 0.96 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| SCHEMBL29272754 | 0.96 | SRC (0.92) | SRCKDREGFRLCKYES1 | |
| SCHEMBL3202847 | 0.94 | SRC (1.00) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4260314 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL29375375 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 | |
| Saracatinib SCHEMBL4260310 | 0.94 | SRC (0.89) | SRCKDREGFRLCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| CN-115769077-A | Methods and compositions for treating cancer | 安锦生物科技私人有限公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | claimed |
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-11-10 | — | — | US | claimed |
| WO-2021202780-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-10-07 | — | — | WO | claimed |
| WO-2021126995-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-06-24 | — | — | WO | claimed |
| US-11000524-B2 | Tyrosine kinase inhibition as a treatment for epilepsy | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-20180153891-A1 | ANTIEPILEPTIC DRUGS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2018-06-07 | — | — | US | claimed |
| US-20170209443-A1 | ANTI-INFLAMMATORY EFFECT OF ORALLY ACTIVE FYN KINASE INHIBITOR SARA-CATINIB (AZD 0530) AGAINST PARKINSON'S DISEASE AND OTHER RELATED NEURODEGENARATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | claimed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | claimed |
| WO-2006064217-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | claimed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | claimed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | claimed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | claimed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | claimed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | claimed |
| EP-1292594-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SRC, BCOR, CTTN | SRC 1/4885ABL1 18/4885KDR 721/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | SRC 1/4885ABL1 26/4885KDR 825/4885 |
| US-11000524-B2 | Tyrosine kinase inhibition as a treatment for epilepsy | FYN, LCK, TYRO3 | SRC 4/4885ABL1 64/4885KDR 161/4885 |
| US-20180153891-A1 | ANTIEPILEPTIC DRUGS | FYN, FGFR3, SYNGR2 | SRC 15/4885ABL1 233/4885KDR 181/4885 |
| US-20170209443-A1 | ANTI-INFLAMMATORY EFFECT OF ORALLY ACTIVE FYN KINASE INHIBITOR SARA-CATINIB (AZD 0530) AGAINST PARKINSON'S DISEASE AND OTHER RELATED NEURODEGENARATIVE DISEASES | FYN, SNCA, SRC | SRC 3/4885ABL1 410/4885KDR 310/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | SRC 1906/4885ABL1 129/4885KDR 1659/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | SRC 3241/4885ABL1 39/4885KDR 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.